Endothelial-monocyte activating polypeptide II, a biomarker for use in diagnosis of brain injury
View Patent ↗A diagnostic tool and method of diagnosing brain injury and brain injury type (traumatic vs. ischemic) by detecting the level of expression of endothelial monocyte-activating polypeptide II (EMAP-II) and comparing to a control. An increase of EMAP-II indicates the presence of traumatic brain injury and a decrease of EMAP-II indicates the presence of ischemic brain injury. Detection of EMAP-II can be done in brain tissue, biofluids such as cerebrospinal fluid or blood (including plasma and serum).
1. A method of diagnosing ischemic brain injury comprising:
a) obtaining a cerebral spinal fluid, blood serum, blood plasma or brain tissue sample from a patient suspected of having brain injury;
b) measuring a level of endothelial monocyte-activating polypeptide II (EMAP II) and/or p43/endothelial monocyte-activating polypeptide II (p43/EMAP II) in said sample;
c) comparing said level to EMAP II and/or p43/EMAP II in a control sample, said control sample obtained from a patient that has no brain injury, wherein if there is a decrease in the level of EMAP II relative to the control, there is ischemic brain injury.
2. The method of claim 1 , wherein the decrease in EMAP II and/or p43/EMAP II is 2.1 to 2.3 fold relative to the normal control for ischemic brain injury.
3. The method of claim 1 , wherein said steps of obtaining and measuring of said levels of EMAP II and/or p43/EMAP II are conducted at between 6 and 48 hours after injury or suspected injury.